Ayunan, Ansar B.
HRN: 24 30 78 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/27/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/27/2023
01/02/2024
IV
600mg
Q8
Sepsis Sec To Facial Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes